Brief: Hybrigenics: Broad-Spectrum Inhibitor Of Ubiquitin-Specific Proteases Shows Antiviral Activity Against Human Adenoviruses
March 26 (Reuters) - HYBRIGENICS SA ALHYG.PA :
* BROAD-SPECTRUM INHIBITOR OF UBIQUITIN-SPECIFIC PROTEASES
SHOWS
ANTIVIRAL ACTIVITY AGAINST HUMAN ADENOVIRUSES
* ON 11 OUT OF 13 VIRAL TYPES TESTED, HBX 47,939 WAS SHOWN
TO
INHIBIT VIRAL REPLICATION IN INFECTED CELLS
* HBX 47,939 WAS SHOWN TO DECREASE PRODUCTION OF NEW VIRIONS
RELEASED IN CULTURE MEDIUM
Source text: https://bit.ly/2ITlGJG
Further company coverage: ALHYG.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Aton SA
See all newsBrief: Hybrigenics SA Says Hybrigenics Re-Brands To 'Aton', Commits EUR 15Million To Support Its New Growth And Development Strategy Over Next Three Years
Brief: Hybrigenics 2022 Net Loss EUR 0.5 Million
Brief: Hybrigenics Presents Progress Of B Cell Design Subsidiary
Brief: Hybrigenics Targets EUR 60 Mln Of Turnover By 2025
Brief: Hybrigenics H1 Operating Loss Widens To EUR 0.2 Million